Abstract
The twentieth century decline in the incidence and prevalence of infectious disease has long been recognised by historians as coinciding with a renewed biomedical focus on the ‘disease management’ of the chronically ill.’ During the 1960s and 1970s the use of ‘risk factors’ — clinical indicators, genetic markers, lifestyle choices, and the like — began to increase the frequency and intensity of similar disease management interventions in seemingly healthy populations. During the past 40 years the global health care industry has engineered hugely profitable markets from healthy ‘patients’ largely by appealing to the value of preventative intervention in the battle against the new diseases of civilisation: hypertension, cancer, and diabetes.2 Ilana Löwy, Robert Aronowitz, and Charles Rosenberg have all recently documented some disturbing trends in disease management directed at the aggressive prevention of anticipated undesirable outcomes.3 New diagnostic tools and larger programmes of more biologically sensitive screening have lead to ever greater ‘early detection’ of ‘pre-cancerous’, ‘pre-diabetic’, and ‘pre-hypertensive’ patient populations. As Aronowitz points out, the experiences and patient-pathways of these ‘pre-patient’ patients can become almost indistinguishable from those patients with serious clinical symptoms of disease.4 While the consequences of this elision between statistical risk of disease and actual organic illness can be relatively benign, Aronowitz, Löwy and Rosenberg highlight at least one dire consequence of this trend: the rising number of healthy but ‘BRCA positive’ women undergoing extremely drastic measures such as prophylactic double mastectomies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Works Cited
Ablin R. 2010, ‘The Great Prostate Mistake’, New York Times, 9 March, A27.
Advanced Particle Therapy 2011, ‘Partnering for the Future of Cancer Treatment’ <http://www.advancedparticletherapy.com/> (last accessed 21 February 2011).
Andriole G. L., Grubb R. L., Buys S. S., Chia D., Church T. R., Fouad M. N., Gelmann E. P., Kvale P. A., Reding D. J., Weissfeld J. L., Yokochi L. A., Craw-ford E. D., O’Brien B., Clapp J. D., Rathmell J. M., Riley T. L., Hayes R. B., Kramer B. S., Izmirlian G., Miller A. B., Pinsky P. F., Prorok P. C., Gohagan J. K. and Berg C. D. 2009, ‘Mortality Results from a Randomized Prostate-Cancer Screening Trial’, New England Journal of Medicine, 360, 1310–19.
Aronowitz R. 2007, Unnatural Histoiy: Breast Cancer and American Society, Cambridge: Cambridge University Press.
Aronowitz R. 2009, ‘The Converged Experience of Risk and Disease’, Milbank Quarterly, 87, 417–42.
Barclay L. 2004, ‘End of an Era for PSA Screening: A Newsmaker Interview With Thomas Stamey, MD’, Medscape Medical News: http://www.medscape.com/view-article/489474 (last accessed 20 February 2011).
Bryder L. 2008, ‘Debates about Cervical Screening: An Historical Overview’, Journal of Epidemiology and Community Health, 62, 284–7.
Casper M. and Clarke A. 1998, ‘Making the Pap Smear into the “Right Tool” for the Job: Cervical Cancer Screening in the USA, circa 1940–95’, Social Studies of Science, 28, 255–90.
Clarke A. E., Mamo L., Fishman J. R., Shim J. K. and Fosket J. R. 2003, ‘Bio-medicalization: Technoscientific Transformations of Health, Illness and US Biomedicine’, American Sociological Review, 68, 161–94.
Dahl O. 2005, ‘Protons. A Step Forward or Perhaps Only More Expensive Radiation Therapy?’, Acta Oncologica, 44, 798–800.
Evans I., Thornton H. and Chalmers I. 2006, Testing Treatments: Better Research for Better Healthcare, London: British Library.
Goffman T. 2004, ‘The Vulnerability of Radiation Oncology within the Medical Industrial Complex’, International Journal of Radiation Oncology Biology Physics, 59, 1–3.
Goitein M. and Cox J. 2008, ‘Should Randomized Clinical Trials Be Required for Proton Radiotherapy?’, Journal of Clinical Oncology, 26, 175.
Goitein M. and Goitein G. 2005, ‘Swedish Protons’, Acta Oncologica, 44, 793–7.
Greene J. 2007, Prescribing by Numbers: Drugs and the Definition of Disease, Baltimore: Johns Hopkins University Press.
Hall E. 2009, ‘Protons for Radiotherapy: A 1946 Proposal’, Lancet Oncology, 10, 196.
Halperin E. 2006, ‘Particle Therapy and Treatment of Cancer’, Lancet Oncology, 7, 676–85.
Hill C. and Laplanche A. 2010, ‘Cancer de la Prostate: Les Données Sont en Défaveur du Dépistage’, La Presse Médicale, 39, 859–64.
Jones B. 2005, ‘Particle Therapy Co-operative Oncology Group (PTCOG 40) Meeting, Institute Curie 2004’, British Journal of Radiology, 78, 99–102.
Jones B. 2006, ‘The Case for Particle Therapy’, British Journal of Radiology, 79, 24–31.
Jones B. and Burnet N. 2005, ‘Radiotherapy for the Future’, British Medical Journal, 330, 979–80.
Jones B. and Rosenberg I. 2005, ‘Particle Therapy Cooperative Oncology Group (PTCOG40)’, British Journal of Radiology, 78, 99–102.
Jordan V. 2009, ‘A Century of Deciphering the Control Mechanisms of Sex Steroid Action in Breast and Prostate Cancer: The Origins of Targeted Therapy and Chemoprevention’, Cancer Research, 69, 1243–54.
Kangan A. and Schultz R. 2010, ‘Proton-Beam Therapy for Prostate Cancer’, Cancer Journal, 16, 405–9.
Keating P. and Cambrosio A. 2002, ‘From Screening to Clinical Research: The Cure of Leukemia and the Early Development of the Cooperative Oncology Groups, 1955–1966’, Bulletin of the History of Medicine, 76, 299–334.
Lawrence E. 1937, ‘The Biological Action of Neutron Rays’, Radiology, 29, 313–22.
Leonhardt D. 2009, ‘In Health Reform, a Cancer Offers an Acid Test’, New York Times, 7 July, Al.
Lerner B. 2001, The Breast Cancer Wars: Hope, Fear, and the Pursuit of a Cure in Twentieth-Century America, Oxford: Oxford University Press.
Lewis T. 1977, ‘On the Science and Technology of Medicine’, Daedalus, 106, 35–46.
Lexchin J. 2011, ‘Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases Outcomes of Clinical Trials of Medications’, Science and Engineering Ethics, 17, Epub ahead of print.
Löwy I. 1996, Between Bench and Bedside: Science, Healing, and Interleukin-2 in a Cancer Ward, Cambridge: Harvard University Press.
Löwy I. 2009, Preventative Strikes: Women, Precancer, and Prophylactic Surgery, Baltimore: Johns Hopkins University Press.
Löwy I. 2012, A Woman’s Disease: The History of Cervical Cancer, Oxford: Oxford University Press.
Makarov D. and Carter H. 2006, ‘The Discovery of Prostate Specific Antigen as a Biomarker for the Early Detection of Adenocarcinoma of the Prostate’, Journal of Urology, 176, 2383–5.
Marks H. 1997, The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900–1990, New York: Cambridge University Press.
Metz J. 2006, ‘History of Proton Therapy’, August 2006, Oncolink.org: http://www.oncolink.org/custom_tags/print_article.cfui?Page=2&id=209&Section=Treatment_ Options (last accessed 7 August 2011).
Nass S., Moses H. and Mendelsohn J. (eds) 2010, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, Washington: National Academy of Sciences: http://www.nap.edu/catalog/12879. html (last accessed 20 February 2011).
The National Association for Proton Therapy 2011, ‘US Proton Therapy Centers’, http://www.proton-therapy.org/map.htm (last accessed 20 February 2011).
National Cancer Institute 2011, ‘Surveillance Epidemiology and End Results. Stat Fact Sheet: Prostate’, http://seer.cancer.gov/statfacts/html/prost.html (last accessed 8 August 2011).
National Prostate Cancer Coalition 2007, ‘Do it for Dad’, http://zerocancer.org/assets/2007_DIFD_Press_Kit.pdf?docID=661 (last accessed 6 July 2011).
Olsen D. R., Bruland O. S., Frykholm G. and Norderhaug I. N. 2007, ‘Proton Therapy — A Systematic Review of Clinical Effectiveness’, Radiotherapy and Oncology, 83, 123–32.
Particle Therapy Cooperative Group 2011, ‘Particle Therapy Facilities on Operation (International)’, http://ptcog.web.psi.ch/ptcentres.html (last accessed 21 February 2011).
Particles, June 1988—January 1994.
Phillips J. and Sinha A. 2009, ‘Patterns, Art, and Context: Donald Floyd Gleason and the Development of the Gleason Grading System’, Urology, 74, 497–503.
Potosky A. L., Miller B. A., Albertsen P. C. and Kramer B. S. 1995, ‘The Role of Increasing Detection in the Rising Incidence of Prostate Cancer’, Journal of the American Medical Association, 273, 548–52.
Potts J. and Walker E. 2010, ‘Isn’t It Time to Abandon Prostate Specific Antigen (PSA) for Prostate Cancer Screening?’, Journal of Men’s Health, 7, 3.
Rao A. R., Motiwala H. G. and Karim O. M. A. 2007, ‘The Discovery of Prostate-Specific Antigen’, BJU lnternational, 101, 5–10.
Rosenberg C. 2009, ‘Managed Fear’, The Lancet, 373, 802–3.
Sakr W. A., Grignon D. J., Haas G. P., Heilbrun L. K., Pontes J. E. and Crisman J. D. 1996, ‘Age and Racial Distribution of Prostatic Intraepithelial Neoplasia’, European Urology, 30, 138–44.
Schröder F. H., Hugosson J., Roobol M. J., Tammela T. L. J., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L. J., Recker F., Berenguer A., Määttänen L., Bangma C. H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B. G., Moss S. M., de Koning H. J. and Auvinen A. 2009, ‘Screening and Prostate-Cancer Mortality in a Randomized European Study’, The New England Journal of Medicine, 390, 1320–8.
Silletti J. P., Gordon G. J., Bueno R., Jaklitsch M. and Loughlin K. R. 2007, ‘Prostate Biopsy: Past, Present, and Future’, Urology, 69, 413–16.
Slater J. 2006, ‘Clinical Applications of Proton Radiation Treatment at Loma Linda University: Review of a Fifteen Year Experience’, Technology in Cancer Research and Treatment, 5, 81–9.
Smith A. 2006, ‘Proton Therapy’, Physics in Medicine and Biology, 51, R491—R504.
Smith A. 2009, ‘Vision 20/20: Proton Therapy’, Medical Physics, 36, 556–68.
Sriprasad S., Feneley M. and Thompson P. 2009, ‘History of Prostate Cancer Treatment’, Surgical Oncology, 18, 185–91.
Stamey T. A., Caldwell M., McNeal J. E., Nolley R., Hemenez M. and Downs J. 2004, ‘The Prostate Spedfic Antigen Era in the United States is Over for Prostate Cancer: What Happened in the Last Twenty Years?’, Journal of Urology, 172, 1297–301.
Stamey T. A., Kabilin J. N., McNeal J. E., Johnstone I. M., Freiha F., Redwine E. A. and Yang N. 1989, ‘Prostate Specific Antigen in the Diagnosis and Treatment of Adenocarcinoma of the Prostate. II. Radical Prostatectomy Treated Patients’, Journal of Urology, 141, 1076–83.
Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. and Redwine E. A. 1987, ’Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate’, New England Journal of Medicine, 317, 909–16.
Stanton J. 2000, ‘Supported Lives’, in R. Cooter and J. Pickstone (eds) Medicine in the Twentieth Centuty, Amsterdam: Harwood Academic, 601–15.
Stone R. and Larkin J. 1952, ‘The Treatment of Cancer with Fast Neutrons’, Radiology, 39, 608–20.
Suit H. 2002, ‘Coming Technical Advances in Radiation Oncology’, International Journal of Oncology Biology and Physics, 53, 798–809.
Timmermans S. and Berg M. 2003, The Gold Standard: The Challenge of Evidence-Based Medicine and Standardization in Health Care, Philadelphia: Temple University Press.
Tobias C. A., Lawrence J. A., Born J. L., McCombs R. K., Roberts J. E., Anger H. O., Low-Beer B. V. A. and Huggins C. B. 1956, ‘Pituitary Irradiation with High-Energy Proton Beams: A Preliminary Report’, Cancer Research, 18, 121.
Turesson I., Johansson K.-A. and Mattsson M. 2003, ‘The Potential of Proton and Light Ion Beams in Radiotherapy’, Acta Oncologica, 42, 107–14.
Vos R. 1991, Drugs Looking for Diseases: Innovative Drug Research and the Development of the Beta Blockers and the Calcium Antagonists, Amsterdam: Kluwer Academic Publishers.
Wilson R. 2004, A Brie f History of the Harvard University Cyclotrons, Cambridge: Harvard University Press.
Yamey G. and Wilkes M. 2002, ‘The PSA Storm. Questioning Cancer Screening Can Be a Risky Business in America’, British Medical Journal, 324, 431.
Editor information
Editors and Affiliations
Copyright information
© 2012 Helen Valier
About this chapter
Cite this chapter
Valier, H. (2012). Uncertain Enthusiasm: PSA Screening, Proton Therapy and Prostate Cancer. In: Timmermann, C., Toon, E. (eds) Cancer Patients, Cancer Pathways. Science, Technology and Medicine in Modern History. Palgrave Macmillan, London. https://doi.org/10.1057/9781137272089_9
Download citation
DOI: https://doi.org/10.1057/9781137272089_9
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-44480-9
Online ISBN: 978-1-137-27208-9
eBook Packages: Palgrave History CollectionHistory (R0)